You are here : Home / Community / Guest

William Schaffner, MD

Background

Dr. William Schaffner is professor and chair of preventive medicine and professor of medicine in the division of infectious diseases at Vanderbilt University School of Medicine in Nashville, Tennessee.

Dr. Schaffner recently served as president of the National Foundation for Infectious Diseases. In addition, he is a member of numerous professional societies, including the Infectious Diseases Society of America, Society of Healthcare Epidemiology of America, and the American Public Health Association.

Dr. Schaffner is active in the field of infectious disease research and has authored or co-authored more than 230 published studies, reviews, and book chapters on infectious diseases. He currently serves on the editorial board of a number of scientific journals, including Journal of Infectious Diseases, European Journal of Clinical Microbiology, and Infectious Diseases and Vaccine.

Dr. Schaffner's work has focused on all aspects of infectious diseases, including epidemiology, infection control and immunizations. In 1996, he was awarded the Society of Healthcare Epidemiology Lecturer Award "in recognition of extraordinary career contributions to infection control and healthcare epidemiology." Dr. Schaffner has worked extensively on the effective use of vaccines in both pediatric and adult populations. He is a strong proponent of collaboration between academic medical centers and public health institutions.

Dr. Schaffner received his medical degree from Cornell University Medical College in New York. He also was a Fulbright Scholar (Albert Ludwigs University, Freiburg, Germany), and received his undergraduate degree from Yale University in New Haven, Connecticut.

 

Affiliations

Vanderbilt University School of Medicine, National Foundation for Infectious Diseases

Disclosures

Dr. Schaffner is or has been an occasional consultant for Pfizer, Novartis, GlaxoSmithKline and Dynavax. He is a member of the Data Safety Monitoring Boards for experimental vaccine trails at Merck.